AGILE THERAPEUTICS INC (AGRX) Stock Overview
USA - NASDAQ:AGRX - US00847L3087 - Common Stock
AGRX Key Statistics, Chart & Performance
The current stock price of AGRX is 0.6022 USD. In the past month the price decreased by -25.49%. In the past year, price decreased by -94.62%.
AGRX Latest News, Press Relases and Analysis
AGRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.11 | 781.26B | ||
| JNJ | JOHNSON & JOHNSON | 18.34 | 458.55B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.76 | 258.24B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.73 | 252.36B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.65 | 235.32B | ||
| MRK | MERCK & CO. INC. | 11.36 | 218.53B | ||
| PFE | PFIZER INC | 7.3 | 140.77B | ||
| SNY | SANOFI-ADR | 14.34 | 125.85B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.51 | 89.21B | ||
| GSK | GSK PLC-SPON ADR | 9.67 | 86.97B | ||
| ZTS | ZOETIS INC | 23.46 | 64.68B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.04 | 44.25B |
Related stock screener links
About AGRX
Company Profile
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. The company is headquartered in Princeton, New Jersey and currently employs 22 full-time employees. The company went IPO on 2014-05-22. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The firm commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.
Company Info
AGILE THERAPEUTICS INC
500 College Road East, Suite 310
Princeton NEW JERSEY 08540 US
CEO: Alfred Altomari
Employees: 22
Phone: 16096831880
AGILE THERAPEUTICS INC / AGRX FAQ
What does AGRX do?
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. The company is headquartered in Princeton, New Jersey and currently employs 22 full-time employees. The company went IPO on 2014-05-22. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The firm commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.
What is the stock price of AGILE THERAPEUTICS INC today?
The current stock price of AGRX is 0.6022 USD. The price increased by 10.11% in the last trading session.
Does AGRX stock pay dividends?
AGRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of AGRX stock?
AGRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of AGRX stock?
AGILE THERAPEUTICS INC (AGRX) operates in the Health Care sector and the Pharmaceuticals industry.
What is the expected growth for AGRX stock?
The Revenue of AGILE THERAPEUTICS INC (AGRX) is expected to grow by 101% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for AGRX stock?
AGILE THERAPEUTICS INC (AGRX) will report earnings on 2024-05-09, before the market open.
AGRX Technical Analysis
AGRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AGRX. AGRX may be in some trouble as it scores bad on both profitability and health.
AGRX Financial Highlights
Over the last trailing twelve months AGRX reported a non-GAAP Earnings per Share(EPS) of -13.33. The EPS increased by 97.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.26% | ||
| ROA | 75.6% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AGRX Forecast & Estimates
7 analysts have analysed AGRX and the average price target is 5.1 USD. This implies a price increase of 746.89% is expected in the next year compared to the current price of 0.6022.
For the next year, analysts expect an EPS growth of 93.92% and a revenue growth 101% for AGRX